<p>Nanosomal Docetaxel Lipid Suspension-Based Chemotherapy in Breast Cancer: Results from a Multicenter Retrospective Study</p>

• DOI: 10.2147/bctt.s236108
• Publication Date: 2020-05-21T22:46:36Z
• Authors: Sundaram Subramanian; Rammohan Prasanna; Ghanashyam Biswas; Saroj Kumar Das M...; Nisarg Joshi; Deepak Bunger; Mujtaba A Khan; Imran Ahmad
• Keywords: Leukopenia; Clinical endpoint

The purpose of this study was to evaluate the efficacy and safety nanosomal docetaxel lipid suspension (NDLS, DoceAqualip)-based chemotherapy in breast cancer.Medical charts patients with cancer, who were treated followed up NDLS (75-100 mg/m2; 3-week cycle)-based from August 2014 to September 2018, analyzed multicenter, retrospective study. endpoints overall response rate (ORR: complete [CR]+partial [PR]) disease control (DCR: CR+PR+stable [SD]) neoadjuvant metastatic settings. Overall survival (OS) evaluated for all settings.Of 91 (neoadjuvant: 12, adjuvant: 61, metastatic: 18), evaluation 29 12/12, 17/18) demonstrated an ORR DCR 100%, respectively, setting, 64.7% 70.6%, setting. At a median follow-up 21.6 months (range: 2.1 to 49.9 months), OS not reached adjuvant settings, it 30.4 least one adverse event (AE) reported 59.3% patients. Anemia, thrombocytopenia, lymphopenia, neutropenia most common hematological AEs while hyperglycemia alteration liver function tests non-hematological AEs. NDLS-based treatment well tolerated without any new concerns.Nanosomal suspension-based efficacious cancer. Further, is being prospectively triple-negative cancer (ClinicalTrials.gov: NCT03671044).